K PharmaTSE:4896 +9.15%11 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates TSE:4896 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, K Pharma ranks worse than 105932.1% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. K Pharma's EBITDA for the
three
months ended in Dec. 2025 was 円0.00 Mil. K Pharma's Revenue for the
three
months ended in Dec. 2025 was 円0.00 Mil. Therefore, K Pharma's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.
K Pharma (TSE:4896) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
K Pharma EBITDA Margin % Related Terms
K Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for K Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4896 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, K Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
K Pharma EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, K Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where K Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
K Pharma (TSE:4896) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on K Pharma and its competitors. Over the past decade, K Pharma's EBITDA Margin % has ranged from 36.61 to 36.61. According to the industry distribution chart, K Pharma ranks #999999 out of 944 companies in the Biotechnology industry.
Is K Pharma's EBITDA Margin % too high?
K Pharma's current EBITDA Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 36.61 to a high of 36.61. Based on the distribution chart, K Pharma ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, K Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does K Pharma's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, K Pharma ranks #999999 out of 944 companies for EBITDA Margin %. This places K Pharma in the lower half of its industry. Historically, K Pharma's own EBITDA Margin % has ranged from 36.61 to 36.61 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on K Pharma and its competitors. K Pharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is K Pharma stock overvalued right now?
K Pharma (TSE:4896) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. K Pharma's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For K Pharma (TSE:4896), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
K Pharma Inc is a company involved in Research, development, manufacturing, sales, and marketing of pharmaceutical products and regenerative medicine products. It is involved in the study of iPs cells in regenerative medicine to treat neurological conditions such as cerebral infarction and SCI.
11GF Score
Get the complete analysis for TSE:4896
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4896 has been successfully added to your 
